文献速递白血病淋巴瘤

维奈克拉联合奥加伊妥珠单抗治疗复发难治性急性淋巴细胞白血病

Venetoclax plus Inotuzumab Ozogamicin for Relapsed and Refractory Acute Lymphoblastic Leukemia.
PubMed 文献 · Blood · 2026-09-25

推荐剂量为维奈克拉400mg/天×21天/周期,无剂量限制性毒性或早期死亡,95.5%可评估患者达完全缓解,MRD清除率高,2年DFS和OS均为48%。

要点

  • 维奈克拉联合奥加伊妥珠单抗在复发难治B-ALL/LBL中安全有效,完全缓解率达95.5%。
  • 推荐剂量为维奈克拉400mg/天×21天/周期,未出现剂量限制性毒性。
  • 常见≥3级不良事件为血小板减少(43.5%)和中性粒细胞减少(39.1%),4例(17.4%)发生窦状隙梗阻综合征。

核心结论

  • 维奈克拉联合奥加伊妥珠单抗对复发难治B-ALL/LBL安全有效,可产生频繁且持久的MRD阴性缓解。

研究设计与样本

  • 剂量递增:3例接受DL1(维奈克拉200mg/天),6例接受DL2(400mg/天),14例进入扩展队列(400mg/天)。
  • 推荐剂量为维奈克拉400mg/天×21天/周期,患者中位接受2周期(范围1-5)。

主要发现

  • 无剂量限制性毒性或早期死亡。
  • 常见≥3级不良事件为血小板减少(43.5%)和中性粒细胞减少(39.1%)。
  • 4例(17.4%)发生窦状隙梗阻综合征。
  • 22例可评估患者中21例(95.5%)达完全缓解,其中19例在1周期后达缓解。
  • MRD经流式细胞术(<10^-4)清除16/18(88.9%),经二代测序(<10^-6)清除14/19(73.7%)。

临床怎么用

  • 对于复发难治B-ALL/LBL,可考虑维奈克拉400mg/天×21天/周期联合标准剂量奥加伊妥珠单抗方案。
  • 治疗中需监测血小板减少、中性粒细胞减少及窦状隙梗阻综合征。
  • 缓解后应评估MRD并考虑桥接HSCT。

局限性

  • 随访时间有限,中位OS未达。
  • 未设对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL), responses to the CD22 antibody-drug conjugate inotuzumab ozogamicin (INO) are frequent but short-lived. Based on preclinical evidence of synergy, we conducted a phase 1 trial of the BCL-2 inhibitor venetoclax (VEN) plus standard-dose INO for adults with R/R CD22+ ALL/LBL. Twenty-three patients enrolled (15 ALL, 8 LBL): three at dose level 1 (DL1; VEN 200 mg/day), six at DL2 (VEN 400 mg/day), and fourteen in an expansion cohort (VEN 400 mg/day). The recommended dose was VEN 400 mg/day for 21 days per cycle. No dose-limiting toxicities or early mortality occurred. Patients received a median of 2 cycles (range 1-5). The most common grade ³3 adverse events were thrombocytopenia (43.5%) and neutropenia (39.1%). Four patients (17.4%) developed sinusoidal obstructive syndrome. Of 22 evaluable patients, 21 (95.5%) achieved complete remission, including 19 after one cycle. Measurable residual disease (MRD) cleared in 16/18 (88.9%) by flow cytometry (<10-4) and 14/19 (73.7%) by next-generation sequencing (<10-6). Fourteen (63.6%) patients proceeded to HSCT. With a median follow-up of 25.3 months (95% CI 19.0-32.4), two-year disease-free (DFS) and overall survival (OS) were 48% (95% CI 24-72%); median DFS was 22.1 months (95% CI 10.4-NA), and median OS was not reached. MRD-positivity was associated with lower baseline BCL-2 dependence. Correlates of progression included acquired MCL-1 dependence, CD22 antigen escape, drug efflux gene ABCB1 expression, and oncogenic mutations. In summary, VEN+INO is safe and effective for R/R B-ALL/LBL, producing frequent and durable MRD-negative remissions. NCT05016947.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Luskin MR, Keating JH, Frost BF, et al. Venetoclax plus Inotuzumab Ozogamicin for Relapsed and Refractory Acute Lymphoblastic Leukemia. Blood. 2026. PMID: 42789493. doi:10.1182/blood.2026035238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。